Sinopharm: Intends to issue H shares and list on the main board of the Hong Kong Stock Exchange.

Senlitai Announcement: The company held the sixteenth meeting of the sixth board of directors on January 21, 2026, and approved the proposals related to the issuance of H shares and listing on the main board of Hong Kong Stock Exchange. In order to further advance the company's globalization strategy, create an international capital operation platform, and support the high-quality development of the company, the company plans to issue overseas shares and apply for listing on the main board of the Hong Kong Stock Exchange.